<DOC>
	<DOCNO>NCT00072631</DOCNO>
	<brief_summary>The purpose study determine erlotinib improve disease dose produce characteristic rash patient advance Non-Small Cell Lung Cancer .</brief_summary>
	<brief_title>Erlotinib ( Tarceva ( Trademark ) , OSI-774 ) Treating Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Only patient 0 1 performance status ECOG scale eligible .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Confirmed diagnosis Stage IIIB IV nonsmall cell lung cancer ( histological cytological ) . Received prior chemotherapy treatment advance , metastatic nonsmall cell lung cancer . Measurable disease per RECIST criterion . Adequate bone marrow , hepatic renal function . Breast cancer skin cancer time past cancer past 5 year . Brain metastasis unstable , require steroid , lifethreatening require radiation last 28 day . Known hypersensitivity minocycline . History serious cardiac disease control . Serious eye condition . Prior treatment inhibitor EGFR kind .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Tarceva</keyword>
	<keyword>erlotinib</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>EGFR</keyword>
	<keyword>OSI-774</keyword>
</DOC>